View Latest Medical and Pharma Bids and Tenders

Supply of Medicine and Medical / Surgical equipments : Pneumococcal Conjugate Vaccine (PCV) 0.5ml\nsingle dose vaccine vial/prefilled syringe\nPneumococcal Conjugate Vaccine (PCV)\nEach 0.5mL single dose vaccine vial/prefilled syringe\nto contain Pneumococcal Conjugate prepared from\nsuitable pathogenic strains of Streptococcus\npneumoniae for subcutaneous or intramuscular use.\nNote:\n1. Vaccines recommended for bulk purchase by the\nWHO for UN agencies will be considered as an\nadded advantage (WHO pre- qualified). etc .

Supply of Medicine and Medical / Surgical equipments : Tetanus Toxoid Adsorbed 0.5ml (single\ndose) Ampoule/vial\nAdsorbed Tetanus Vaccine BP single dose\n(0.5mL)\nOR\nTetanus Toxoid Adsorbed USP single dose\n(0.5mL)\nEach 0.5mL single dose ampoule/vial should\ncontain an estimated potency of not less than\n40 units of Tetanus Toxoid. The vaccine to\ncontain Tetanus Toxoid produced by the\ngrowth of Clostridum Tetani in the form of\nTetanus Formol Toxoid.\nNote:\n1. Offers should be only from vaccine suppliers\nrecommended by World Health Organization\nfor bulk purchase for U.N. Agencies (WHO pre-\nqualified).\n2. The following documents should be\nsubmitted pre- shipment for each lot of vaccine\ndispatched. (a)Invoice (b) Certificate of origin\n(c) Certificate of analysis (d)Lot release\ncertificate from National control\nLaboratory(NCL) from country of\norigin.(e)Summary lot protocols of production\nprocedure & quality control testing. These\ndocuments should be submitted pre-shipment\nto the National Control Laboratory for Vaccines\n(MRI) Sri Lanka.\n3. The product should be from fresh stocks and\neach consignment should be prepared\npreferably from a single batch.\n4. The product should have a minimum 2/3 of\nremaining shelf life at the time of delivery at\nMSD.\n5. The vaccine should also comply with the\ngeneral requirements for vaccines in the\nBP,USP or other pharmacopeial standards\napproved by NMRA, Sri Lanka.\n6. Cold Chain monitors or WHO recommended\nother cold chain monitoring device should be\nincluded for each carton and the cold chain etc .

Supply of Medicine and Medical / Surgical equipments : Bacillus Calmette-Guerin Vaccine (BCG) 20\ndose vial (with a suitable diluent)\nBacillus Calmette-Guerin vaccine (BCG) 20\ndose Vial\nBacillus Calmette-Guerin vaccine BP or USP\n(BCG Vaccine)\nEach infant (<1 year old) dose should contain\n0.025mg of live Bacillus Calmette - Guerin and\nwhen reconstituted, the dose should be 0.05mL\n1.Offers should be only from vaccine suppliers\nrecommended by World Health Organization\n(WHO) for bulk purchase for the UN Agencies.\n2. The product should be from fresh stocks\nand each consignment should be prepared\npreferably from a single batch. Each batch\nshould accompany a certificate of analysis, lot\nrelease certificate issued by a laboratory\naccredited by National Control Authority and\nSummary Protocol of vaccine production and\nquality control test data should be submitted for\nprotocol review.\n3. Each consignment should have a minimum\nremaining shelf life of 75% at the time of\nreceiving the consignment at MSD.\n4. The vaccine should also comply with the\ngeneral requirements for vaccines in the BP or\nUSP.\n5. The vaccine should meet the most recent\nrequirements of WHO when tested by the\nmethods outlined by WHO.\n6. Vaccine should be stored at a temperature\nof 2'C-8'C. Cold chain monitors or WHO\nrecommended other cold chain monitoring\ndevice should be included in each pack during\ndelivery and the cold chain should be\nmaintained during storage, transport and\ndelivery of vaccines.\n7. Each vial to be provided with a suitable\nsterile diluent.\n8. Each vial should contain a suitable vaccine\nvial monitor.\n9. Must be a WHO prequalified product. etc .

Supply of Medicine and Medical / Surgical equipments : Adsorbed Diphtheria and Tetanus\nVaccine (DT) 10 dose vial\nAdsorbed Diphtheria and Tetanus\nVaccine(DT),10 dose vial. Adsorbed\nDiphtheria and Tetanus Vaccine BP or USP.\nEach 0.5ml single dose containing not less\nthan 30 international units (IU) of Diphtheria\nToxoid and not less than 40 IU of Tetanus\nToxoid.\ni.Offers should be only from vaccine\nsuppliers recommended by World Health\nOrganization (WHO) for bulk purchase for\nthe U.N. Agencies.\nii.The product should be from fresh stocks\nand each consignment should be prepared\npreferably from a single batch. Each batch\nshould accompany a certificate of analysis,\nlot release certificate issued by a laboratory\naccredited by National Control Authority and\nSummary Protocol of vaccine production\nand quality control test data should be\nsubmitted for protocol review.\niii.Each consignment should have a\nminimum remaining shelf life of 75% at the\ntime of receiving the consignment at MSD.\niv.The vaccine should also comply with the\ngeneral requirements for vaccines in the BP\nor USP.\nv.The vaccine should meet the most recent\nrequirements of WHO when tested by the\nmethods outlined by WHO.\nvi.Cold chain monitors or WHO\nrecommended other cold chain monitoring\ndevice should be included in each pack\nduring delivery and the cold chain should be\nmaintained during storage, transport and\ndelivery of vaccines.\nvii.The vaccine should be protected from\nlight and should be stored at a temperature\n+2'C to +8'C. Vaccines should not be frozen.\nviii.Each vial should be labeled accordingly\nindicating both date of manufacture and\nexpiry.\nix.Must be a WHO prequalified product.\nx.Each vial should contain a suitable vaccine\nvial monitor. etc .

Supply of Medicine and Medical / Surgical equipments : Bivalent Poliomyelitis Vaccine Live 10\ndose vial (with a suitable dropper)\nBivalent Poliomyelitis Vaccine Live Oral\n(bOPV)10 dose vial Bivalent Poliomyelitis\nVaccine Live BP,EP or USP Liquid stabilized\npreparation of live attenuated poliomyelitis\nvirus of the Sabin strains type 1 and type 3.\nEach immunizing dose of vaccine should\ncontain not less than 10 6 TCID50 for type 1\nand 10 5.8 TCID50 for type 3 (should\nconform to the formulation of ratio of 10:6 for\nvaccine virus sero type 1 and 3\nrespectively). One immunizing dose should\nbe contained preferably in two drops.\ni.Offers should be only from vaccine\nsuppliers recommended by World Health\nOrganization (WHO) for bulk purchase for\nthe U.N. Agencies.\nii.The product should be from fresh stocks\nand each consignment should be prepared\npreferably from a single batch. Each batch\nshould accompany a certificate of\nanalysis,lot release certificate issued by\nlaboratory accredited by National Control\nAuthority and Summary Protocol of vaccine\nproduction and quality control test data\nshould be submitted for protocol review.\niii.Each consignment should have a minimu\nm remaining shelf life of 75% at the time of r\neceiving the consignment at MSD.\niv.The vaccine should also comply with the\ngeneral requirements for vaccines in the\nBP,EP or USP.\nv.The vaccine should meet the most recent\nrequirements of WHO when tested by the\nmethods outlined by WHO.\nvi.Cold chain monitors or WHO\nrecommended other cold chain monitoring\ndevice should be included in each pack\nduring delivery and the cold chain should be\nmaintained during storage, transport and\ndelivery of vaccines.\nvii.The vaccine should be protected from\nlight and should be stored at a temperature -\n20'C. etc .

Supply of Medicine and Medical / Surgical equipments : Varicella Vaccine Live 0.5ml, single dose vial etc .

Supply of Medicine and Medical / Surgical equipments : Hepatitis B Vaccine single dose vial etc .

Supply of Medicine and Medical / Surgical equipments : Pneumococcal Vaccine single dose vial etc .

Supply of Medicine and Medical / Surgical equipments : Pneumococcal conjugate Vaccine (PCV) etc .

Supply of Medicine and Medical / Surgical equipments : Antirabis inactivated issued culture vaccine\nfor animal use in 10 dose vial\nAntirabies inactivated tissue culture vaccine for\nanimal use in 10 dose vial\nNote:\n1.Must be an inactivated Tissue Culture Vaccine\ncontaining OIE recommended vaccine strain\n(inactivation procedure, adjuvant and\npreservatives/excipients used in the vaccine\nshould be mentioned).\n2.Potency should be equal to or more than 1 IU\nper dose.\n3.Each consignment should have a minimum\nremaining shelf life of 75% at the time of\nreceiving the consignment at MSD.\n4.Must be in 10 Dose Vials.\n5.Must provide protective immunity for a period of\n03 years in vaccinated animals.\n6.The product must be registered at the\nVeterinary Drug Control Authority of the\nDepartment of Animal Production and Health of\nSri Lanka.\n7.A detailed, set of literature of recent studies\n(within the past 03 years) to illustrate the efficacy\nof the relevant vaccine brand in the target\nspecies, especially dogs (sample size should be\nmore than 25 dogs), must be submitted.\n8.All new offers which do not have past\nexperience for use in mass vaccination\nprogram/s against Rabies in Sri Lanka should\nprove the efficacy of the vaccine through a field\nserological study conducted at a WHO/OIE\nreference laboratory.\n9.Performance record : Performance guarantee\nshould be submitted to prove that the product\nhas been sold to use in mass vaccination\nprograms with a minimum of 500,000 doses in a\nsingle consignment at least twice in the past 5\nyears in rabies endemic countries (other than the\ncountry of manufacture of the vaccine).\n10.Vaccine should be transported at the\ntemperature range of 2'- 8'c .\n11.Sticker should be provided for each dose\n(Label with vaccine brand name, batch no and\nexpiry date).\n12.Certificate of GMP of the manufacturer as\nstipulated by WHO ? OIE must be provided.\n13.Product with past complaints or failures will\nnot be considered.\n1